Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Mission Produce heads into the final stretch of 2026 with two stories pulling in opposite directions: short sellers are quietly paring back positions while the company's dominant activist shareholder keeps building.
Short interest has eased meaningfully this week, falling around 11% over the past seven days to roughly 7.8% of the free float, about 5.5 million shares. That is still a material short position for a small packaged-foods name, but the direction of travel has shifted. The pullback follows a spike in late September, when shorts briefly pushed above 6.2 million shares on September 29, the highest level in the 30-day window. Borrow conditions give little urgency to either side. Cost to borrow is running at just under 0.7%, essentially negligible, and availability is a comfortable 241%, meaning there are more than two shares available to borrow for every one already out on loan. That is well above the 52-week tightest reading of 124%, suggesting no squeeze pressure is building. The ORTEX short score has eased from 70.9 on September 29 to 66.2 this week, consistent with a position that is unwinding rather than building. Options traders are meanwhile leaning heavily bullish: the put/call ratio at 0.051 is below the 20-day average of 0.061 and near its lowest levels in a year, a setup where call volume dominates the options market.
The activist angle is arguably the most newsworthy fact about this stock. Globalharvest Holdings Venture Ltd has an active Schedule 13D on file, last amended July 9, and is a genuine activist on the SEC register. The filing marks its eighth amendment since first filing in June 2025, and the position has grown from 11.93% to 14.01% of shares, a purchase of nearly 600,000 shares at $13.28 each in early July, worth close to $7.9 million. That puts Globalharvest as the single largest shareholder by a wide margin. The executive chairman, Stephen Barnard, sits just below with 6.2%, though he has been a seller in recent weeks, offloading shares on at least six separate occasions between September 11 and September 24, with total open-market sales across those trades approaching $2.5 million at prices around $12.54 to $13.10. None of those sales were filed as part of a pre-arranged 10b5-1 plan. The contrast is worth noting: the company's largest outside shareholder is accumulating at the same price range where the executive chairman is exiting. As always with 13D/G filings, positions are as last disclosed around the 5% threshold and holders dropping below that level are not required to file again.
On the institutional side, two other names added meaningfully in recent quarters. Rubric Capital Management entered as a 6.8% holder after adding over 4.2 million shares, and BlackRock lifted its stake to around 5.3%, adding 1.3 million shares per its most recent filing. Fourth Sail Capital also appears in the top ten after buying nearly 2.9 million shares. Against that, co-founder Luis Gonzalez trimmed slightly. The overall holder count of 144 institutions is modest for a Nasdaq-listed name.
The Street remains thinly covered. Roth Capital reiterated its Buy rating and $17 target in September, the only action within recent memory from a named firm. At the current price of $12.51, that implies roughly 36% upside to the mean analyst target of $16.50, though that consensus figure carries a June 2026 timestamp and should be treated as directional rather than precise. Valuation looks undemanding: the EV/EBITDA multiple has compressed around 0.76 points over the past month to just under 9 times, and the forward earnings yield has nudged higher. The 12-month forward EPS growth rank scores in the 98th percentile of the ORTEX universe, a standout, though the EPS surprise score at just the 5th percentile flags a track record of missing near-term estimates. That tension, strong long-run growth expectations against a weak history of beating the quarter, sits at the heart of the bull-bear debate.
From the company's own filing data, the ORTEX Alt Data layer flags that buyback spend in the second quarter fell 58% against the same period a year earlier, to $2.2 million. The remaining buyback authorisation also hit its smallest Q4 level on record since 2023. Neither dataset carries a measured lead to reported revenue, so no forward read-through is appropriate, but the shrinking buyback activity does reduce one potential source of technical support beneath the stock.
The next earnings event is scheduled for December 18. Between now and then, the most relevant question is whether the Globalharvest accumulation continues, and whether the executive chairman's open-market selling at current prices is an isolated cluster or the start of a longer distribution.
See the live data behind this article on ORTEX.
Open AVO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
